Background: Infantile hemangiomas (IHs) are the commonest soft tissue tumors of infancy, with an incidence of 4% to 10% of children. Despite showing spontaneous regression following the initial proliferative phase, about 30% of cases may ulcerate, show massive growth, cause disfigurement or impact normal developmentor appearance. Common locations for problematic hemangiomas include the face, ear, orbit and airways. These hemangiomas may subsequently require early and aggressive treatment,to achieve ideal functional and cosmetic outcomes. In this study, we present the efficacy of oral propranolol in infants younger than 24 months of age, with infantile hemangiomas. This prospective cohort included 32 patients with infantile hemangiomas, attending the vascular anomalies’ outpatient clinic at Cairo University Specialized Pediatric Hospital, between June 2016 and June 2018, who were treated with oral propranolol. Patients were evaluated after 7 days of treatment and then every month for a minimum of 6 months. Monthly evaluation consisted of clinical and photographic evaluations of the lesions and monitoring of treatment compliance and tolerance. Results: The mean age of patients was 5.48 months at the point of starting the treatment (range: 3-12 months) and was 11.64 months (range: 9-18 months) at the time of stopping the treatment. Eight males and 24 females (M:F = 1:3) were included in the study. The mean reduction of the lesion size was 36.85% (SD 11.9).Complications recorded in this study were as follows, 2 cases developed hypoglycemia (6.25%), 2 cases developed relapse after stopping the medication (6.25%) and 1 case developed hyperactivity/reactivity of the airways (3.2%). Twenty-seven cases (84%) suffered no complications, and the treatment was well tolerated in these. Conclusion: Propranolol is the 1st line of treatment in IHs. It is safe and well tolerated with minimal side effects. Keywords: Infantile Hemangioma; Oral Propranolol; Beta Blockers.